Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.
about
Vaccines against malariaImmune mechanisms in malaria: new insights in vaccine developmentTransgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccinesVaccines for preventing malaria (pre-erythrocytic)Stage-dependent localization of a novel gene product of the malaria parasite, Plasmodium falciparumInduction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adultsCircumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malariaDevelopment and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.Genetic immunisation by liver stage antigen 3 protects chimpanzees against malaria despite low immune responses.Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates.Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraInduction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum.gammadelta T cells are a component of early immunity against preerythrocytic malaria parasites.Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivoDevelopment of vaccines against human parasitic diseases: tools, current status and perspectives.Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoeliiVectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in micePersistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations.Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis.Advances and challenges in malaria vaccine development.Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.The RTS,S vaccine candidate for malaria.Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hostsImmunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.Efficacy of Phase 3 Trial of RTS, S/AS01 Malaria Vaccine in infants: a systematic review and meta-analysis.Towards a blood-stage vaccine for malaria: are we following all the leads?Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsImpact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigensCpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccineP. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections.Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.Medicinal application of long synthetic peptide technology.
P2860
Q17485685-ACA920FB-4454-47D0-8ADC-1394A8EB1C9BQ21032484-8FFCEFF3-AA9A-44DB-A1FB-32BEDBB82EFBQ21032495-2F56339A-0FBB-4448-AE07-6B6E3ED42150Q24244317-F2AAC595-5E97-4445-A9ED-F543E4F1BECDQ27972741-C4D10A9F-8644-4599-A595-FAFB533033C9Q28741242-FE859DA5-56CE-49D4-9F46-38411FB8F6BBQ28744149-1FBAD593-1BEF-4B4C-83A1-34C3F6F003CFQ28744170-F6A0C54F-D68F-4FC2-9A75-097BE2284622Q30413695-52019698-B8D0-40A2-B336-F884BEAEC505Q33351936-2DCC45D2-2C8D-4523-B7A7-396F6825FAB6Q33489512-D674CA9B-3EA2-4759-A6FA-4505C927ECABQ33512921-6D8C07E2-CBAE-4BA8-801E-DC0BB9D9E265Q33521372-D471F65D-537A-4266-8A8F-482904A0A484Q33524699-F551CA65-8AC2-4569-9D96-7258EBA81C4CQ33935092-ED72799E-78CF-4B93-BCA8-B40AE7462685Q33943869-3B55DD68-EB17-453E-8FD6-C3089685FA99Q33960093-49A99A7E-F766-4EDC-91E0-6DBDDC3E0646Q34003993-C54CE812-638B-45F7-90C0-239DE1731495Q34004839-371C239C-BEC7-4BDF-B067-D04B2FF1A5BEQ34074704-C5F53EE3-8952-4DAC-AFB9-B0839DB4E485Q34109763-DAC6E611-0550-4E56-991A-261F9ABE87C0Q34119885-0B228B85-7DFA-43EF-87D2-456C58915437Q34126483-A31E1331-FE9E-47E6-A355-D8302BD92B19Q34127607-52F46A70-19F0-488E-B2BA-CF5DDC1F5E34Q34145333-262024BD-C993-4AA0-B9CD-A3FB17206272Q34170122-0B87456F-FF36-42ED-9F8F-D0D8FEFE05B6Q34186762-A67A4693-B1FA-47B1-A351-A975C6A67CB2Q34258733-08DDB415-3E51-4466-9001-CF2332798C4EQ34261339-B62BA8F9-B8F4-4222-B105-D3BC4F6571FEQ34301004-D51FC3CF-EE6A-4CD6-BB0F-ED1C062DFCA2Q34416103-5D94CCEA-2AE1-42EA-B41D-7065746BCCBAQ34546220-76A5C361-D313-40F2-8D63-0DF3B88F8CC4Q34548672-9110DB87-2E6A-4F28-9E3E-8ED00FEFEE4FQ34572160-4812F960-C219-4D2D-B517-0C87479B37F2Q34634002-48AA3616-2B24-4DDB-B86F-62496BAAF43DQ35330733-1D669092-CB27-408F-BAEE-91F86D06838BQ35550770-6E41E5CE-F397-4F62-8710-AB3B7F388951Q35561160-33EA43B0-B43F-46A9-8D5F-DBAAA50B5193Q35684141-E406D62A-9020-4F15-8346-8129DE7FB7B1Q35907030-072AA9CF-DF31-497C-BFC0-C89D3EAF64A1
P2860
Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Long-term efficacy and immune ...... ith the RTS,S malaria vaccine.
@en
Long-term efficacy and immune ...... ith the RTS,S malaria vaccine.
@nl
type
label
Long-term efficacy and immune ...... ith the RTS,S malaria vaccine.
@en
Long-term efficacy and immune ...... ith the RTS,S malaria vaccine.
@nl
prefLabel
Long-term efficacy and immune ...... ith the RTS,S malaria vaccine.
@en
Long-term efficacy and immune ...... ith the RTS,S malaria vaccine.
@nl
P2093
P356
P1476
Long-term efficacy and immune ...... ith the RTS,S malaria vaccine.
@en
P2093
P304
P356
10.1086/515657
P407
P577
1998-10-01T00:00:00Z